Summary
Bayer is offering $7.25 billion to settle claims in the U.S. that its Roundup weedkiller causes cancer. The settlement aims to resolve ongoing legal issues that arose after Bayer bought Monsanto, the original maker of Roundup. The proposal needs a judge's approval and involves payments over 21 years, mainly targeting patients with non-Hodgkin lymphoma.
Key Facts
- Bayer has proposed a $7.25 billion settlement to address claims that Roundup causes cancer.
- The settlement is part of Bayer's effort to resolve legal issues linked to its 2015 purchase of Monsanto.
- Bayer has already paid about $10 billion for Roundup-related lawsuits.
- A judge must approve the new settlement for it to proceed.
- The settlement primarily concerns non-Hodgkin lymphoma cases, a type of blood cancer.
- Patients exposed to Roundup before February 17, 2023, and diagnosed within 16 years can receive payments.
- The bulk of the $7.25 billion payout will occur in the first five years, over a total of 21 years.
- Bayer also expects to pay $3 billion for other Roundup-related cases, including state claims about chemical usage.
